Ista petitions FDA over eye drug label

03/6/2011 | Reuters

Ista Pharmaceuticals sent a petition asking the FDA to reject any generic version's application for the withdrawn twice-daily eye medicine Xibrom that uses the original labeling. Ista said any generic's label should include a reference to the option of the once-daily dose.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC